News Features Reimbursement Issues Seem to Be Holding Renal Denervation Back Todd Neale December 19, 2024
News Features Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question L.A. McKeown August 09, 2024
News Features The Promise of Pulsed-Field Ablation: Cautious Optimism Amid Some Unknowns Todd Neale March 29, 2024
News Features FDA Clears AI-ECG Screening Tools for CV Care: What’s Next Is Up for Grabs Yael L. Maxwell December 14, 2023
News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Features Expired Cardiac Devices May Do Global Good, but Safety Unknown Yael L. Maxwell August 26, 2021
News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020
News Features Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good Todd Neale December 14, 2020
News Features As US Cardiologists Mull a Biden Presidency, COVID-19 Trumps All Todd Neale November 13, 2020
News Features Mechanical Circulatory Support in COVID-19: Mixed Results, Hints of Hope Caitlin E. Cox June 02, 2020
News Features Hydroxychloroquine: No Help, Clear Harm in COVID-19 RCT and Cohort Studies Shelley Wood May 20, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020
News Features Trial by Twitter: How a 280-Character Count Is Reshaping Cardiology Michael O'Riordan March 03, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Features Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses Shelley Wood December 23, 2019
News Features Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too Michael O'Riordan December 18, 2019